Minerals and vitamins in bone health: the potential value of dietary enhancement by Bonjour, Jean-Philippe et al.
Review Article
Minerals and vitamins in bone health: the potential value of dietary
enhancement
Jean-Philippe Bonjour1*, Le´on Gue´guen2, Cristina Palacios3, Martin J. Shearer4 and Connie M. Weaver5
1Division of Bone Diseases, University Hospital, Rue Micheli-Du-Crest, 1211 Geneva, Switzerland
2Human Nutrition and Food Safety, French National Institute for Agricultural Research (INRA), Paris, France
3Department of Human Development, Program of Nutrition, Graduate School of Public Health, University of Puerto Rico,
San Juan, PR, USA
4Vitamin K Research Unit, Centre for Haemostasis and Thrombosis, St Thomas’s Hospital, London, UK
5Department of Foods and Nutrition, Purdue University, West Lafayette, IN, USA
(Received 13 June 2008 – Revised 8 January 2009 – Accepted 9 January 2009 – First published online 1 April 2009)
Nutrition is important to bone health, and a number of minerals and vitamins have been identified as playing a potential role in the prevention of
bone diseases, particularly osteoporosis. Despite this, there is currently no consensus on maximum levels to allow in food or as dietary sup-
plements. The benefits of supplementation of populations at risk of osteoporosis with Ca and vitamin D are well established. Prolonged supplemen-
tation of Ca and vitamin D in elderly has been shown to prevent bone loss, and in some intervention studies to prevent fragility fractures. Although
P is essential to bone health, the average intake is considered to be more than sufficient and supplementation could raise intake to adverse levels.
The role of vitamin K in bone health is less well defined, though it may enhance the actions of Ca and vitamin D. Sr administered in pharma-
cological doses as the ranelate salt was shown to prevent fragility fractures in postmenopausal osteoporosis. However, there is no hard evidence
that supplementation with Sr salts would be beneficial in the general population. Mg is a nutrient implicated in bone quality, but the benefit of
supplementation via foodstuffs remains to be established. A consensus on dietary supplementation for bone health should balance the risks, for
example, exposure of vulnerable populations to values close to maximal tolerated doses, against evidence for benefits from randomised clinical
trials, such as those for Ca and vitamin D. Feedback from community studies should direct further investigations and help formulate a consensus
on dietary supplementation for bone health.
Calcium: Phosphorus: Vitamin D: Vitamin K: Strontium: Magnesium
With the ageing of the population, particularly in Europe, the
financial impact on national healthcare systems associated
with the management of the diseases of the elderly is expected
to increase dramatically in the coming years(1). Bone diseases
will represent a sizable proportion of these costs. The world-
wide financial impact of osteoporotic fractures is estimated
to double by 2050 to reach 76·7 billion euros(2 – 4). In Europe,
hospitalisation costs for hip fractures alone currently represent
more than 3·5 billion euros each year(3,4).
In 1994, the WHO defined osteoporosis as a disease
‘characterized by low bone mass and microarchitectural
deterioration of bone tissue, leading to bone fragility and a
consequent increase in risk of fracture’(5). In Europe, it is
estimated that 179 000 men and 611 000 women suffer a hip
fracture every year(6), and these numbers are expected to
double in the next 40 years, as the demographic situation in
Europe evolves and the population ages(4). Although the
whole population is at risk, the likelihood of developing osteo-
porosis increases according to various factors including sex,
age, family or fracture history, and Caucasian or Asian
ethnic origins(7 – 9). Nevertheless, preventive measures are
also important since, for example, lack of exercise, smoking,
and alcohol consumption have also been identified as risk fac-
tors(10,11). A diet rich in vitamin D and Ca is also recognised
as playing a major role in the prevention of osteoporosis(7,12).
Osteomalacia is due to a defect of bone mineralisation
resulting in weakened and fragile bones and could also lead
to hip fractures(13). It is the adult equivalent of rickets in
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children and affects approximately 1 in 1000 individuals in
Western societies(14). Like rickets, osteomalacia is mainly
caused by insufficient exposure to sunlight uncompensated
by the dietary intake of vitamin D(13). Some defects in vitamin
D metabolism or action can also lead to impaired bone matrix
mineralisation(13). Renal diseases and phosphate depletion are
also among the major causes of osteomalacia(13). Maintaining
appropriate intakes of vitamin D, if sunlight exposure is insuf-
ficient, and Ca constitutes the best prevention strategy.
Nutrition should form part of bone disease prevention strat-
egies(15), especially in the light of the ageing of the population
and the effect of diet on bone health. Bone mass peaks at
about the age of 18 years and, at skeletal sites such as the
proximal femur, it declines thereafter with an acceleration
after 50 years of age(7). The acquisition of bone mineral
mass during childhood, adolescence and early adulthood is
an important factor determining the risk of osteoporosis in
later adult life. Nevertheless, to what extent modifications
in environmental factors, such as nutrition and/or physical
activity, can influence the risk of osteoporotic fracture in
late adhultbood is not known(16).
Because of the influence of cultural environment on nutri-
tional habits, there are very differing opinions on the subject
of dietary enhancement and bone health, even regarding the
health benefits and safety of the numerous vitamin and mineral
supplements available. Although the value of nutrients such as
Ca and vitamin D for bone health is well established,
a European consensus on maximum levels to allow in food
supplementation is still lacking. Moreover, P, vitamin K, Sr
and Mg have also been cited as playing a role in bone
health. The present paper aims to review the minerals and
vitamins that are currently being discussed as part of a
supplementation strategy to prevent bone disease. We will
therefore discuss Ca, P, vitamin D, vitamin K, Sr and Mg.
For each, we examine the bone health benefits, the risks, inter-
actions, and consequences on health, and the normal dietary
intake and deficiencies, in order to review the safety and the
need for supplementation. As a strategy for finding the most
relevant publications we performed a detailed search in the
main scientific available databases.
General description of dietary recommendation designations
In the present review, recommended dietary intake (RDI) is
used as a generic designation for reference or recommended
values for population nutrient intakes. Otherwise, the precise
term by the national authority that sets the reference or
recommended value is used. In France, RDI for Ca and P, as
designated by the term ‘apports nutritionnels conseille´s’, is
similar to the former US RDA. In the USA and Canada, the
term ‘dietary reference intake’ was more recently adopted as
nutrient reference standards, in replacement of the former
Canadian RDI and US RDA. Dietary reference intake includes
the ‘estimated average requirement’, RDA, ‘adequate intake’
and ‘tolerable upper intake level’. As clearly defined by
Barr(17), estimated average requirement is the average daily
intake level that meets the requirements of 50 % of healthy
individuals in a life stage and sex group, whereas the RDA
is set at a level that will meet the requirements of almost all
(97·5 %) individuals in that life stage and sex group. An ade-
quate intake is a recommended intake level that is thought to
meet the needs of almost all healthy individuals, and is set
when there are insufficient data to establish an estimated aver-
age requirement and therefore an RDA. The tolerable upper
intake level represents a threshold above which adverse effects
of excessive intake may increase. In the USA, dietary refer-
ence intake corresponds to RDA for P and Mg and to adequate
intake for Ca, vitamin D and vitamin K. In the UK, ‘reference
nutrient intake’, ‘estimated average requirement’ and ‘lower
nutrient reference intake’ are used for nutrients with sufficient
data to set one recommended level. The term ‘safe and ade-
quate intake’ is used when too few studies are available to
set the other dietary reference values.
Calcium
Bone health and benefits
In the form of hydroxyapatite, Ca10 (PO4)6 (OH)2, Ca and P
constitute the mineral substance of the skeleton and teeth,
which contain 99 % of the adult body’s Ca and over 80 % of
its P. These two elements therefore play a major role in
bone strength and are of prime nutritional importance in
osteoporosis(18). Bone loss can be slowed in the elderly by
Ca intake, which reduces the risk of hyperparathyroidism,
which in turn promotes bone resorption. The importance of
Ca supplementation for bone health is well established and,
together with vitamin D, is considered as a key component
of any preventive or therapeutic regimen for osteoporosis(18).
The beneficial effect of long-term Ca and vitamin D
supplementation on bone and fracture risk in elderly women
has also been documented in several clinical trials(18 – 21).
A recent report from the Women’s Health Initiative (WHI)
study(22) indicated that prolonged Ca supplementation (plus
vitamin D) in healthy postmenopausal women significantly
improved bone mineral content (BMD) at the hip. A signifi-
cant 29 % relative decrease in the risk of hip fracture was
recorded, but only among participants who adhered to the
Ca þ vitamin D supplementation(22). A large study in the
UK, the Randomised Evaluation of Calcium Or vitamin D
(RECORD) trial(23) did not find significant anti-fracture
efficacy associated with supplementation, but this study had
poor compliance and analysed the secondary prevention of
fracture. Two recent meta-analyses of randomised controlled
trials concluded that additional Ca is needed with vitamin D
to reduce the risk of hip fracture and highlighted the
importance of compliance with supplementation in reducing
fracture risk(24,25).
Nutritional properties. Although Ca has numerous vital
functions and is implicated in the incidence of several patho-
logical disorders, the physiological requirements for this
element have been principally established on the basis of
bone criteria(26 – 28). As bone also serves as a hormonally
mediated exchangeable reservoir of Ca and P, which is
mainly intended to maintain blood Ca at normal levels, it is
considered that, by meeting the requirements of bone, the
extracellular and intracellular needs of other tissues will also
be covered.
Intake from diet. A good proportion of dietary Ca
(60–70 %) comes from milk and dairy products. In most
European countries(29), cheeses in adults and yoghurts in
children and teenagers are particularly important sources of
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Ca. With the exceptions of almonds, dried fruit, small bony
fish, and a few green vegetables, common foodstuffs are
poor in Ca(29,30). Where flour is fortified with Ca as in the
United Kingdom, foods such as bread, biscuits and cakes
can make a substantial contribution to total Ca intake. Some
mineral waters are rich in calcium bicarbonate, while others
are particularly rich in calcium sulfate.
RDI for Ca vary between countries and regions. There is
no consensus in Europe, adult RDI varying from 700 mg/d
(reference nutrient intake)(27) in the UK to 1000 mg in Aus-
tria, Germany, Switzerland and The Netherlands. In France,
RDI are 900 mg/d in adults(28) and 1200 mg/d for adolescents,
postmenopausal women and the elderly. The American daily
adequate intakes are 1000 mg for adults, 1300 mg for adoles-
cents, and 1200 mg for postmenopausal women and the
elderly(26).
Necessity to enhance the calcium intake. Recent surveys
in France have indicated that mean Ca intake is 1040 mg/d
for boys and 820 mg/d for girls between 10 and 18 years of
age, 850 mg/d for male adults under 65 years and 790 mg/d
over 65 years, 770 mg/d for women under 50 years and
690 mg/d over 50 years, and 500 to 600 mg/d for elderly
women in residential care(28). This suggests that there is a
need for enhancing Ca intake, preferably by the consumption
of more Ca-rich foods, in teenage girls (200–300 mg/d),
postmenopausal women and the elderly (250–300 mg/d), and
elderly women in residential care (500–600 mg/d).
These values relate to median intakes in individuals with
a diet containing dairy products. However, a diet that
does not include dairy products cannot provide more than
400–450 mg Ca/d, unless intake of Ca-rich mineral water is
high. In such cases, the need for Ca enhancement is greater
and could reach 650 mg/d.
Maximal levels of intake
In France, the upper limit of Ca intake deemed safe when con-
sumed for a prolonged period is 2 g/d, compared with 2·5 g/d
in the American recommendations and by the Scientific
Committee on Food of the European Commission(31). This
Commission considered that the data were insufficient to
derive an upper limit value for children from that of 2·5 g/d
set for adults(31). Hypercalcaemia, alkalosis, and renal and
other ectopic calcifications may result if these limits are regu-
larly exceeded over a long period. For example, in the WHI
study, in which the average Ca intake was 2·15 g/d (combined
with vitamin D) over 7 years in postmenopausal women,
there was a 17 % increase in kidney stones(22), though this
may have occurred in subjects who were taking additional
Ca supplementation, which was allowed in this trial. High
doses of Ca can also reduce the absorption of other essential
minerals, such as Fe, Zn and Mg(32). The UK Food Standards
Agency did not establish a safe upper limit for total dietary
Ca(33), but suggests daily doses of supplementary Ca not
higher than 1·5 g/d(34). A diet rich in dairy products, plus
mineral water containing high concentrations of Ca, can pro-
vide more than 2 g Ca/d, and a supplement would not then
be advisable. In most cases, except with a dairy-free diet,
the prescribed daily dose should not exceed 400–500 mg
Ca/d for nutritional purposes, which is less than the maximum
dose of 800 mg/d adopted in France.
Choice of calcium supplementation
Solubility and bioavailability. The water solubility of the
Ca supplement is not a precondition of its biological
efficacy, since the intestinal absorption of Ca depends little
on solubility in food(35). The intestinal absorption of Ca
from the insoluble calcium carbonate salt is as good as that
of Ca from various organic sources and from milk(36 – 42).
However, solubility should be taken into account for the
enrichment of beverages or when supplements are presented
as liquids. In the case of powder or tablets, the solubility of
the salt is not determinant, except in the extreme cases
of highly insoluble salts that are resistant to stomach acids.
Bioavailability in the gut and for bone is the first criterion to
take into account when selecting a Ca salt. Good intestinal
absorbability is required, but it is only the first step in terms
of bioavailability for both bone mineral accretion and
bone loss prevention, particularly in the elderly. Some dietary
factors influence bone Ca accretion and/or resorption, as well
as urinary Ca excretion. Thus, all these factors will determine
the overall bioavailability of various Ca salts.
Mineral or organic salts. Various Ca salts are already
authorised for the manufacture of food supplements: mineral
salts such as carbonate, chloride, oxide, hydroxide and
phosphate, and organic salts such as citrate, gluconate, glycer-
ophosphate, pidolate and lactate. Comparative studies have
been done on all these salts, and their bioavailability in the
intestine is deemed good, at about 25–35 % for moderate
intakes, which is of the same order of magnitude as the Ca
of milk, which is often taken as a reference(41). Other Ca
salts are the subjects of requests for exemption from Directive
2002/46/EC authorising use in food supplements, inasmuch
as they are already marketed for this purpose in the European
Community(43).
Several Ca salts or complexes of amino acids, glycinate,
L-aspartate, L-lysinate and L-methionate, which are already
authorised as sources of amino acids, pose no problem of
toxicity and, despite a lack of data in human subjects, the
bioavailability of Ca is probably good, but not significantly
better than that of mineral salts. The malate (already author-
ised as a food additive, E 352), pyruvate and succinate salts
of Ca are well-known organic acid salts and can be unreserv-
edly authorised. Malic acid is abundant in various fruits and
vegetables, and several studies have shown that the bioavail-
ability of calcium citrate-malate is very good, and often
greater than that of the Ca of milk(41,44). The value of a
pyruvate or succinate salt is less clear, and no evidence of
the safety of a high intake has been published. Other organic
sources, such as calcium ethanolamine phosphate and calcium
orotate, are probably bioavailable, but nothing guarantees the
safety of the anionic moiety, several grams per d of which
would be ingested at the doses prescribed for Ca. A Ca chelate
of amino acids, principally in the form of bisglycinate, is
often presented as a source of Ca with excellent absorbability,
notably due to chelation, which protects it until it reaches the
site of absorption. Unfortunately, published studies are too
scarce to confirm this.
Calcium silicate is authorised as an additive in food
technology, but cannot be considered as a source of Ca. It is
an inert and insoluble substance whose bioavailability in
the gut is certainly very low. Anhydrous or hydrated calcium
Dietary supplementation and bone health 1583
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sulfate is already authorised in the European Union as a food
additive (E 516). The absorbability of the Ca is probably
good(45). However, excess sulfate is likely to increase urinary
loss of Ca and therefore decrease the efficacy of its bone reten-
tion(46). In addition, maximum supplementation of 800 mg
Ca/d with this salt would provide nearly 2 g sulfate/d, which
is close to the laxative dose, particularly as the consumption
of sulfate-rich mineral water would raise intake to .3 g/d.
Finally, dietary intake of sulfate well below the previous
doses appears to be responsible for the production of hydrogen
sulfide in the colon by sulfate-reducing bacteria, which can
damage the epithelium(47). The deleterious effects of excess
sulfate on urinary loss of Ca and on the epithelial structure
of the colon were not taken into account in an approval formu-
lated by the European Food Safety Authority(48). Before
stating that high doses of calcium sulfate are completely
safe, it would be advisable to conduct further clinical studies.
Phosphorus
Bone health and benefits
Like Ca, the nutritional requirements for P are determined
by bone criteria. The current French RDA are 750 mg P/d
in adults and 800 mg P/d in adolescents and the elderly(28).
Similar values are reported in the USA (700 mg/d in all age
groups)(26), but lower values in the UK (550 mg/d in
adults)(27).
In contrast to Ca, all common foodstuffs (milk, meat, eggs,
vegetables and cereals) are naturally rich in P, whose mean
intake in Europe ranges from 1300 to 1600 mg/d(28). P intake
may be greater in the case of excessive consumption of
foods (for example, ham, processed cheese, surimi) to which
phosphate salts, notably polyphosphates, are used as additives.
This additional intake of P from processed foods can amount
to about 100 mg/d in France, but it can be much higher in the
USA(49). P deficiency is therefore rare in humans and so
supplementation would be pointless, or even harmful, except
in unusual cases of low-energy diets or the regular use of
antacids, which render P insoluble, or in patients with
hypophosphataemic osteomalacia. A tricalcium phosphate
supplement was shown to be efficacious in the prevention of
hip fractures(19), but its main purpose is to supply Ca without
decreasing the Ca:P ratio (close to 2 in tricalcium phosphate,
compared with just 0·6 in the diet).
Risk, nutritional interactions, and consequences on bone
health
Systematic excess of dietary P is inevitable since P content
cannot be reduced in common foods(28). This relative excess
of P, compared with Ca, is likely to increase blood phosphate
levels, which could lead to Ca metabolism disorders because
of a drop in the plasma concentration of ionised Ca, and sec-
ondary hyperparathyroidism. This adverse effect of excess P
on bone remodelling and on the incidence of osteoporosis
has been studied extensively and should not be over-
looked(49 – 52). Other potential consequences of P excess are
ectopic calcifications, particularly in the kidney, diarrhoea,
mild gastrointestinal symptoms, and interactions with the
intestinal absorption of certain trace elements (Fe, Cu
and Zn). P supplementation would then worsen the situation
and even sometimes exceed the safety limit of 2·5 g/d adopted
in France(28).
Upper tolerable intake levels for P were established in the
USA in 1997 at 3 g/d for infants and adolescents and 4 g/d
for adults(26). These levels took into account the observations
that P is not toxic, there are few studies showing an effect
of a high intake on parathyroid hormone (PTH) secretion
associated with bone loss, and PTH can exert an anabolic
action on osteoblastic formation. However, these high
upper levels have been questioned(28). Studies indicating the
absence of an effect of excess P used only moderate levels
(1·6–2·3 g/d) or diets containing sufficient Ca, particularly
from milk and cheese(53,54). Conversely, a high P intake associ-
ated with low Ca and/or vitamin D supply gives rise to second-
ary hyperparathyroidism(49) favouring an increase in bone
resorption or an inactivation of the first stages of bone for-
mation(55). Moreover, excess P decreases renal synthesis of
calcitriol(49).
The conclusions of a more recent and extensive European
review of the effects of high P intakes(56) did not support
the suggestion that induced temporary hyperparathyroidism
due to high P intake increases bone resorption, stating that
normal healthy individuals can tolerate P intake up to at
least 3 g/d without adverse systemic effects. Among the
thirteen cited studies concerning the effect of high P intake
on serum PTH and bone, only two were less than 11 years
old(57,58) and did not report a significant effect. However,
the Ca intake in these trials was sufficient for the requirements
of young adult men (800 mg/d)(57) or very high (1995 mg/d)
for young adult women(58).
According to another expert group of the Food Standards
Agency(33,34), using the same published data, changes in
PTH levels were found in supplemental studies in postmeno-
pausal women with reduced BMD and a history of fractures,
and in healthy men. Changes in plasma Ca and PTH have
been associated with intakes $1500 mg supplemental P/d.
The expert group could not establish a safe upper limit for
total inorganic P, but estimated that a total intake of
2400 mg/d would not be expected to result in any adverse
effect when regularly consumed over a long period. This
value is in good agreement with a previous estimation(28)
and takes into account all the potential deleterious effects
(nephrocalcinosis and gastrointestinal symptoms) as end
points to derive an upper level and a no-observed-adverse-
effect level of 250 mg supplemental P/d. The maximum
daily intake of 450 mg P/d from supplements defined in
France corresponds to P combined with a large intake of
calcium phosphate with a view to supplying Ca, and could
be lowered. Higher levels of P intakes are unnecessary, even
for food technology, and should be avoided.
Futhermore, a recent report suggests that higher serum
P levels are associated with an increased risk of CVD(59).
This increased risk appears to be unrelated to chronic renal
failure or prior CVD. However, it is not established whether
this epidemiological association is related to the P intake
per se or alternatively to an anomaly in the tubular reabsorp-
tion of P, the main physiological determinant of the serum P
level. Furthermore, since a high serum P concentration leads
to lower circulating levels of ionised Ca, which, in turn,
will tend to increase PTH secretion, the possible role of
J.-P. Bonjour et al.1584
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hyperparathyroidism in the incidence of CVD documented in
this observational study cannot be ruled out(59).
Vitamin D
Vitamin D has been the focus of much interest and research in
the past decade. The roles of vitamin D in Ca absorption
and in preventing rickets and osteomalacia in adults are well
established. Recent work on methods for vitamin D analysis
of foods and serum has enabled more populations to be sur-
veyed for vitamin D status. Surprisingly, vitamin D deficiency
and insufficiency are widespread, even at geographical
locations near the equator, due to the inability to synthesise
adequate vitamin D on exposure to the sun because of dark
skin, or habits that limit exposure to UVB radiation. Interven-
tion and dose–response studies have shown health benefits at
higher levels than were previously thought to be the upper
limit deemed to be safe when exposed for a prolonged period.
Bone health and benefits
Nutritional properties. Vitamin D can come from the diet or
from subcutaneous production from 7-dehydrocholecalciferol
upon exposure to UVB radiation. There is rapid conversion
to cholecalciferol, which is slowly converted to 25-hydroxyvi-
tamin D (25(OH)D) by the liver. Serum levels of this metab-
olite are considered to be the best indicator of vitamin D
status. Renal conversion of small amounts of 25(OH)D to
the active form of vitamin D, 1,25-dihydroxyvitamin D
(1,25(OH)2D), occurs in response to PTH levels, which
increase when serum Ca levels fall or if serum concentrations
of inorganic phosphate are low. This form of vitamin D acts
on the intestine to enhance active Ca absorption by up-regulat-
ing synthesis of Ca transport proteins and on the bone to
increase resorption. These actions occur in order to maintain
serum Ca levels within the normal range. Without
1,25(OH)2D, Ca absorption would occur only by the passive,
intercellular route(60).
Although rickets and osteomalacia have long been associ-
ated with vitamin D deficiency rather than inadequate
production of 1,25(OH)2D, there has been a rejuvenated
interest in the direct effect of 25(OH)D on bone. Adult
serum 25(OH)D levels are more positively associated with
Ca absorption efficiency than are serum 1,25(OH)2D
levels(61,62), and supplementing with vitamin D or 25(OH)D
increases Ca absorption efficiency(63). In contrast, serum
1,25(OH)2D, but not 25(OH)D, predicts Ca absorption in
children, as would be expected by the classic model for
homeostatic regulation by the vitamin D–PTH axis(64).
Serum 25(OH)D levels have been inversely related to serum
PTH levels in both adults(19,65) and children(64,66,67). In the
elderly, increased bone resorption is the main concern with
secondary hyperparathyroidism. In children, despite suppres-
sion of serum PTH, vitamin D status or supplementation has
little impact on bone measures(64,68,69). One study showed a
modest benefit to bone in Lebanese girls given higher levels
of vitamin D3 than in other studies, i.e. 14 000 IU (350mg)/
week, for 1 year(70). This resulted in significant benefits in
gain of total hip bone mineral content (BMC) and area, but
not at other sites including femoral neck, trochanter, and
total body(70).
Lean mass increased significantly with vitamin D sup-
plementation, which can have an impact on bone through
increased muscle mass stress. One study has shown significant
advantages of 400 IU (10mg)/d vitamin D supplementation on
bone mineral accretion at the spine and femur in 11-year-old
Danish girls(71). However, another study suggested that
larger doses may be necessary to increase BMC in Pakistani
immigrant adolescent girls in Denmark(72).
In contrast to children, there is increasing evidence that
higher vitamin D status and vitamin D supplementation can
positively influence predictors of osteoporosis and fracture
in adults. In the Third National Health and Nutrition Examin-
ation Survey (NHANES III), serum 25(OH)D was positively
associated with hip BMD in 13 432 subjects aged 20 years
and older within the reference range of the Diasorin assay
for serum 25(OH)D(73). A meta-analysis of five randomised
controlled trials on hip fracture and seven on non-vertebral
fracture showed that vitamin D intakes of 700–800 IU
(17·5–20mg)/d reduced the relative risk (RR) of hip fracture
by 26 % (RR 0·74; 95 % CI 0·61, 0·88) and non-vertebral
fracture by 23 % (RR 0·77; 95 % CI 0·68, 0·87) compared
with the control group(74). Two large trials in the UK, the
RECORD trial(23) and one by Porthouse et al. (75), and one
in the USA, the WHI(22), did not achieve significant anti-frac-
ture efficiency with vitamin D supplementation. This may be
due to low vitamin D levels of supplementation in the case
of the WHI trial or to poor compliance in the RECORD and
WHI trials. The size of the effect with 800 IU (20mg) vitamin
D1/d in the Porthouse et al. trial
(75) was similar to that of the
meta-analysis(74), but the CI was much wider and included the
number 1. The conclusion of two other meta-analyses(24,76)
underscored that the beneficial effect on hip fracture preven-
tion required the combination of vitamin D with Ca and
appeared to be stronger in frail elderly confined to institutions,
as shown in the classical trial by Chapuy et al. (19).
Bischoff-Ferrari et al. (77) conducted a meta-analysis of
randomised controlled trials for the relationship between
serum 25(OH)D and the risk of falling. Pooled data from
1237 subjects from five trials showed that vitamin D
supplementation reduced the risk of falling by 22 %(77). Fall
reduction may be more pronounced in less active older
women, but physical activity and vitamin D may not be
related in older men(78). Assessment of lower-extremity func-
tion through functional measures, such as the sit-to-stand test
and the 8-foot walk test, have been measured as predictors of
fracture risk because muscle function is thought to indicate
susceptibility to falls(79,80). Muscle-specific 1-hydroxylases
convert 25(OH)D into 1,25(OH)2D in muscle, and nuclear
receptors for 1,25(OH)2D have been identified that lead
de novo protein synthesis and improved muscle function(74,81,82).
Lower-extremity function increased throughout the reference
range of serum 25(OH)D, but especially up to 40 nmol/l,
in 4100 ambulatory elderly adults who participated in
NHANES III(73). In Lebanese children, vitamin D supplemen-
tation increased accrual of lean mass over 1 year, which
explained much of the effect of vitamin D supplementation
on total hip BMC and area accrual(70).
Intake from diet. In the absence of adequate exposure
to sunlight, the current American dietary reference intake
for vitamin D in the form of cholecalciferol is 200 IU
(5mg)/d for adults, rising to 600 IU (15mg)/d in the elderly
Dietary supplementation and bone health 1585
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(.70 years)(26). However, most of the daily input of vitamin
D comes from cutaneous synthesis rather than from diet.
Moreover, the inadequacy of food composition databases
with respect to vitamin D limits an accurate estimate of
intake, beyond the usual difficulties individuals experience
in accurately remembering and recording their food consump-
tion patterns. Thus, vitamin D intake from diet is not evaluated
in most studies.
Natural food sources are mostly fatty fish, fish liver oils, and
the fat of fish-eating animals. In countries such as Northern
Europe where fatty fish is a major constituent of the diet,
intakes of vitamin D have been estimated to be as high as
236 IU (5·9mg)/d for women and 272 IU (6·8mg)/d for
men(52). In countries where fortification is prevalent, vitamin
D-fortified foods are the major dietary source of vitamin D.
Vitamin D status is the highest in countries with mandatory
vitamin D fortification, i.e. the USA and Canada for milk
and margarine, and lowest in countries with little or no
vitamin D fortification (including Europe)(52). A recent
estimate of average vitamin D intakes in the USA from
NHANES III was ,400 IU (,10mg)/d(83). Intakes in UK
were estimated as half that in the USA. It could be explained
by less use of vitamin D supplements as well as by reduced
levels of fortification of dairy products with vitamin D com-
pared with the USA(52). The levels of fortification in the
USA range from 100 IU (2·5mg) vitamin D per cup (237 ml)
of milk or fortified juice to more modest amounts in cereal
bars, cheese and other processed foods(84). Quality control of
the levels of vitamin D added to foods has been a problem
because of the lack of a quick, reliable test for vitamin D in
foods at the site of manufacture and difficulties associated
with dispersing and stabilising this fat-soluble vitamin(85).
Necessity to supplement a normal diet. A number of indi-
viduals and groups have called for an increase in vitamin D
intakes over current recommendations. The criterion for the
current requirements and the proposed higher levels of
vitamin D intakes are based on adequate serum levels of
25(OH)D. When the current requirements were set, the strat-
egy was to use observed population ranges in serum levels
of 25(OH)D. However, serum levels vary with habits that
affect sunlight exposure, skin type and colouring, and, to a
lesser extent than previously thought, geographical location
relative to the equator(86).
More recently, efforts have been focused on optimal serum
25(OH)D levels for various functional outcome measures. For
adults, Bischoff-Ferrari et al.(78) evaluated the evidence for a
threshold serum 25(OH)D level for establishing optimal
vitamin D status for multiple bone-related outcomes as out-
lined above, as well as other health outcomes, and concluded
that serum 25(OH)D concentrations should be at least
75 nmol/l, and, better still, between 90 and 100 nmol/l. This
level is in line with recommendations of others(87 – 89), but
remains a subject of debate(87). To achieve this level through
diet would require average vitamin D intakes of 1700 IU
(42·5mg)/d(89) and possibly more for dark-skinned individ-
uals(84). The recent emphasis on dietary sources stems from
increasing reports that input from sunlight is becoming
inadequate for many populations due to habits that limit
sunlight exposure, skin type and pigmentation, and concern
about the link between sunlight exposure and melanoma.
Clearly, the intakes required to achieve the vitamin D status
recommended by some cannot be achieved by diet alone
given the current food supply. In fact, such intakes would be
difficult to achieve from vitamin D supplements available to
date. Only recently have vitamin D supplements been made
commercially available that could be used to achieve intakes
approaching 2000 IU (50mg)/d. Calvo et al. (52) estimated
that dietary supplements in some countries contribute 6 to
47 % of the average vitamin D intakes, and this can be
predicted to grow with the increased availability of vitamin D
supplements.
Risk, nutritional interactions, and consequences on bone
health
Given the low levels of vitamin D in natural foods, dietary
vitamin D excesses are rare. Reports of hypervitaminosis D
have occurred with accidental overdoses.
The risks of hypervitaminosis D are typically associated
with hypercalcaemia arising from a vitamin D-dependent
increase in the intestinal absorption of Ca and bone resorption.
Adverse effects can include polyuria, pain, conjunctivitis,
anorexia, fever, chills, thirst, vomiting and weight loss.
Hypervitaminosis D can also lead to calcification of soft
tissue(26). The risk of vitamin D intoxication can be monitored
by measuring several biochemical indices to ensure they
fall within normal ranges. According to the US Food and
Nutrition Board(26), cases of vitamin D intoxication were
associated with serum 25(OH)D ranging from 400 to
1250 nmol/l and serum Ca from 2·82 to 4·00 mmol/l, i.e. mark-
edly above the respective normal ranges.
The upper level set by the US Food and Nutrition Board in
1997 was 1000 IU (25mg)/d for infants and 2000 IU (50mg)/d
for all other ages based on a no-observed-adverse-effect
level of 2400 IU (60mg)/d for hypercalcaemia using evidence
in the literature before 1997(26). The European Commission
Scientific Committee on Food also identified an upper level
of 2000 IU (50mg)/d using a similar approach(26). The UK
Expert Group on Vitamins and Minerals set an even lower
upper level of 1000 IU (25mg)/d(33). Upper levels curtail
food fortification, vitamin supplement manufacturers, and
policy makers, with legal consequences. Significant additional
information has become available since the upper levels were
set in 1997 in the USA, notably several dose–response
studies. Using the risk assessment methodology for the current
upper levels, but with new evidence, Hathcock et al.(90)
suggested that the upper level for adults could be increased
to 10 000 IU (250mg) vitamin D3/d. The trials used to propose
this level lasted for weeks or months, but not years, and none
was conducted in children. Lacking longer-term data and
evidence in children creates some uncertainty when consider-
ing fortification policies that would affect all individuals.
Vitamin D requirements and safety levels are dependent
upon Ca intakes(91). For bone health, vitamin D input is
more important during dietary Ca inadequacy. A recent
meta-analysis concluded that vitamin D supplementation
required additional Ca to be effective and reduce risk of hip
fracture(24). Risk of hypercalcaemia due to vitamin D excess
is greater with high Ca intakes and may lead to increased
risk of kidney stones(22). However, throughout life vitamin D
is still essential for bone health even when Ca intake is high.
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Maximum levels for supplementation
A requisite for considering increases in levels of fortification
of foods or for increases in public policy recommendations
for vitamin D intakes is an increase in the upper levels. A
vitamin D intake recommendation of 1000 IU (25mg)/d has
been recommended(78). In the USA, vitamin D fortification
is optional in most cases for milk with 100 IU (2·5mg) per
cup (236·5 ml)(92). The American dietary guidelines suggest
consuming three cups of milk daily. Such a diet would provide
little more than 300 IU (7·5mg)/d and the rest would need to
come from supplements in the absence of sufficient sun
exposure. In this example, that would mean approximately
700 IU (17·5mg)/d, although some vitamin D would come
from other fortified foods. In European countries, supplements
would need to provide $850 IU (21·3mg) vitamin D/d. Yet,
the benefits of fortification of foods with vitamin D on
health outcomes have not been appropriately evaluated in
any country. Only small trials in subpopulations have shown
the benefit of vitamin D-fortified milk on bone(93,94).
Vitamin K
Rationale for role of vitamin K in bone health
The rationale for a role of vitamin K in bone health originated
from the isolation of a vitamin K-dependent protein from bone
called osteocalcin (or bone Gla protein) in 1975. This discov-
ery followed the unravelling of the molecular role of vitamin K
as an essential cofactor for a post-translational modification,
whereby target peptide-bound glutamate (Glu) residues are
converted to g-carboxyglutamate (Gla) residues(95). Osteocal-
cin is the most abundant non-collagenous protein of the bone
extracellular matrix, and is synthesised by osteoblasts. The
central portion of the molecule contains a highly conserved
Gla domain that facilitates high-affinity binding to hydroxya-
patite. The precise molecular role of osteocalcin is unclear, but
it appears to act as a regulator of bone remodelling and min-
eralisation(96). Another bone Gla protein, matrix Gla protein
(MGP), is a powerful inhibitor of calcification of cartilage.
The essential role of MGP in human bone development is
demonstrated by the heterogeneous embryopathy, chondrodys-
plasia punctata, which is characterised by pathological skeletal
calcification, including that of the growth plate(97). The antic-
alcification activity of MGP depends on the integrity of its five
Gla residues, and chondrodysplasia punctata has been shown
to be caused by maternal warfarin use or vitamin K deficiency
and by congenital MGP mutation(97). Other Gla proteins
present in bone are protein S and Gas6 and the recently
discovered periostin(98). Besides its central role in coagulation,
protein S is synthesised by osteoblasts and hereditary protein S
deficiency has been associated with osteopenia. Gas6 is known
to participate in several cellular processes including bone
differentiation and resorption. Periostin is secreted by bone
marrow-derived mesenchymal stromal cells and, unusually
for a Gla protein, contains four consensus g-carboxylase
recognition sites(98). In vitro studies have shown that carboxy-
lated periostin is localised to bone nodules formed by
mesenchymal stromal cells, suggesting a role in extracellular
matrix mineralisation(98).
The presence of at least five Gla proteins in bone and
cartilage, together with evidence of the essentiality of vitamin
K-dependent modification for their function, present a power-
ful argument for the need for an optimal supply of vitamin
K(95,98,99). We already know that MGP plays an important
role in early bone development and that a degree of undercar-
boxylation of osteocalcin is a common finding in many
populations(100), young and old. This suggests that an adequate
vitamin K status may be necessary for bone health throughout
life. This view is strengthened by recent evidence that
periostin, the latest bone-associated Gla protein to be discov-
ered, plays key roles in the processes of bone development
and repair(98).
Bone health and benefits
Nutritional properties. Vitamin K is the family name for
several biologically active 2-methyl-1,4-naphthoquinones,
which possess a variable isoprenoid side chain at the
3 position. Historically, they have been classified as the
single plant member, phylloquinone (vitamin K1) with a
phytyl side chain, and a series of bacterial menaquinones
(vitamins K2) with multi-prenyl side chains. The latter are
designated menaquinone-n (MK-n) according to the number
(n) of prenyl units. The most common bacterial forms have
long side chains, typically MK-7 to MK-9. MK-4 is not a
common bacterial form, but can be synthesised in vivo from
dietary phylloquinone. This seems to occur by complete
side-chain removal to menadione with subsequent prenylation
of this intermediate(101). Since both phylloquinone and MK-4
are substrates for g-glutamylcarboxylase, this conversion
points to a unique role for MK-4, independent of the recog-
nised coenzyme function of vitamin K.
Different forms of vitamin K have different metabolic
properties. For instance, MK-7, a constituent of the ancient
Japanese food natto (fermented soyabean), has a longer half-
life and greater efficacy for carboxylating osteocalcin than
vitamin K1
(102). More work is needed to determine whether
the in vivo synthesis of MK-4 means that this isoprenologue
has unique actions intrinsic to the geranyl-geranyl side chain.
Intake from diet. The major form of vitamin K in most
diets is phylloquinone from plant sources. FFQ-derived esti-
mates of relative intakes of phylloquinone and MK in the
Netherlands suggest that about 90 % of total vitamin K intakes
are provided by phylloquinone, 7·5 % by MK-5 to MK-10,
and 2·5 % by MK-4(103). In Europe and the USA, at least
half of total phylloquinone intakes come from vegetables
and vegetable products, of which a quarter to a third comprises
green leafy vegetables(104 – 106). With the exception of animal
livers, the most common dietary source of long-chain MK is
fermented foods, such as cheeses and natto.
National surveys reveal considerable variations in phyllo-
quinone intakes within the same population(104 – 106). In two
UK surveys of older (1994–5)(105) and younger individuals
(2000–1)(106) there was an approximate 10-fold difference
between the lower 5th and the upper 95th, although the
arithmetic means were similar at approximately 80mg/d.
Average intakes in the USA (using similar methodology) are
comparable but with a trend to higher intakes in older
adults(104). The UK data also suggest a decline in intakes of
phylloquinone in the adult population from 1986 to 2001(106).
Necessity to supplement a normal diet. Current estimates
of requirements are based on the coagulation function of
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vitamin K rather than on bone health considerations. The cur-
rent UK ‘safe and adequate’ intake of 1mg/kg body weight
per d is based on limited dietary restriction studies of the
intakes needed to maintain a satisfactory coagulation status
and was set in 1991 before any information on dietary intakes
was available. It is fortuitous that this adequate intake is
virtually identical to average UK intakes(105,106). The revised
adequate intake set by the USA in 2001 on the basis of repre-
sentative dietary intake data is 120 and 90mg/d for men and
women, respectively(107). While the US committee noted the
interest in new indicators sensitive to vitamin K intake, such
as undercarboxylated osteocalcin (GluOC), they did not use
them to establish an estimated average requirement because
of ‘uncertainty surrounding their true physiological signifi-
cance and the lack of sufficient dose–response data’.
There is a wealth of evidence that a substantial proportion
of individuals in the UK and USA fail to meet their national
dietary guidelines intakes for vitamin K. In the UK over
50 % of both older(105) and younger adults(106) had intakes
below the recommended safe intake and this proportion rises
to about 75 % if the benchmark for adequacy is taken as the
US adequate intake values.
Population studies in different healthy groups have found
that a low dietary consumption of vitamin K is associated
with an increased fracture risk(108,109) or a lower bone
mass(110), and that an impaired vitamin K status is associated
with low bone mass(111) or increased bone turnover(112). One
caveat to these findings is that they are not consistent for
the same outcome measures of fractures and BMD, or for
age or sex. This may reflect a weak association between
vitamin K intakes and bone health, or indicate that certain
population groups are more vulnerable to vitamin K deficits
than others. Another caveat is that low dietary intakes of phyl-
loquinone could reflect a poor diet in general, and may merely
reflect deficiencies of other nutrients important to bone health.
More convincing evidence has come from several epide-
miological studies that have found that high circulating
GluOC levels constitute an independent risk factor for bone
fracture(113 – 115) and low BMD(116,117). The strength of these
studies is that GluOC is an accepted functional marker of
the vitamin K status of the bone matrix and that this associ-
ation has been found in more than one country with different
methodologies for measuring GluOC. This is coupled with the
knowledge that increased carboxylation of osteocalcin is
readily achievable by dietary supplementation with vitamin K.
Most of the vitamin K intervention studies published to date
have been carried out in Japan with high pharmacological
doses (generally 45 mg/d) of MK-4 (menatetrenone) as a
potential anti-osteoporotic agent. These studies represent a
medical intervention rather than nutritional supplementation
in patients with pre-existing involutional or secondary osteo-
porosis or osteopenia. A recent meta-analysis of published,
randomised controlled intervention trials with vitamin K
suggested a strong association of menatetrenone supplemen-
tation with reduced fracture incidence, as well as an effect
in reducing bone loss(118). This meta-analysis also included
two positive Dutch trials using phylloquinone at doses of
either 10 mg phylloquinone/d in endurance athletes or 1 mg/d
in postmenopausal women. The latter 3-year intervention
study did not have a vitamin K group alone, but compared a
group taking combined vitamins K and D (with Ca and
additional minerals) against a group receiving vitamin D
with Ca and additional minerals and a group taking a
placebo(119). Only participants taking combined 1 mg phyllo-
quinone, 320 IU (8mg) vitamin D and minerals showed a
slowing of bone loss at the site of the femoral neck, but not
at the lumbar spine.
There are two published randomised, controlled supplemen-
tation trials in healthy elderly subjects that have employed
amounts of vitamin K that are potentially achievable from
the diet(120,121). The first was a 2-year trial carried out in
healthy, older Scottish women(120) who were randomised to
four groups to receive daily (i) placebo; (ii) 200mg phylloqui-
none; (iii) 400 IU (10mg) vitamin D3 plus 1 g Ca; or (iv) com-
bined 200mg phylloquinone and 400 IU (10mg) vitamin D3
plus 1 g Ca. This study showed no significant intervention
effect on bone loss between groups, but did show a significant
increase in BMD and BMC in group (iv) at the site of the
ultradistal radius, but not at other sites in the hip or
radius(120). It is of interest that a meta-analysis of studies
examining the effects of vitamin K antagonists also showed
that the ultradistal site was the bone site that was most respon-
sive to loss of bone after exposure to oral anticoagulants(122).
This effect of vitamin K antagonists seems to mirror the find-
ings of vitamin K supplementation in the Scottish women,
albeit in reverse. Overall, the opposing effects of phylloqui-
none in this Scottish study and the effects of vitamin K
antagonists on BMD were both modest. The second study
was a 3-year, controlled trial in healthy elderly North
American men and women(121) randomised to two groups to
receive daily either (i) 500mg phylloquinone, 400 IU (10mg)
vitamin D3 plus 600 mg Ca or (ii) 400 (10mg) vitamin D3
plus 600 mg Ca. This study showed no effect of the extra
500mg phylloquinone (taken in addition to recommended
amounts of Ca and vitamin D) on bone health as assessed
by changes in BMD (femoral neck, spine, or total body) or
biochemical markers of bone turnover(121). There was no
difference between the results in men and women.
Risks, nutritional interactions, and consequences on bone
health
Concept of differential tissue requirements for vitamin K:
mechanistic feasibility considerations. The ability to assess
the degree of undercarboxylation of individual Gla proteins
in the body has led to the concept of tissue-specific require-
ments for vitamin K with greater intakes being required to
maintain the carboxylation of osteocalcin in bone compared
with Gla coagulation proteins in the liver(100). A key question
is to find out whether the epidemiological associations shown
for high circulating GluOC and fracture risk can be explained
on a mechanistic basis. We are hampered in this regard by a
lack of knowledge of the molecular function(s) of osteocalcin.
For example, osteocalcin-knockout mice have an increased
bone formation, and seemingly stronger bones(123). However,
new evidence suggests that osteocalcin is responsible for
subtle changes in the mineralisation process and the matu-
ration of bone mineral crystals that does not show up in
most assessments of bone mineralisation(96). This might
explain why some have postulated that vitamin K has a greater
effect on bone quality than density, implying that BMD
measurements alone may not reflect vitamin K’s effects(124).
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This view is supported by recent reports that vitamin K
improves hip bone geometry and bone strength indices(125,126).
If undercarboxylation of osteocalcin were very harmful,
we might expect to see pronounced effects in patients on
long-term warfarin therapy. In fact this is not the case,
though a meta-analysis suggested an overall detrimental
effect of warfarin on BMD(122).
Whether or not GluOC is detrimental to bone health, a sub-
stantial and sustained increase in the g-carboxylation status of
osteocalcin is readily achievable by dietary supplementation
with nutritionally relevant amounts of phylloquinone. This
was clearly seen in the Scottish(120) and American(121) inter-
vention studies in which daily supplementation with 200 and
500mg phylloquinone respectively resulted in an approximate
average 50 % reduction in the fraction of total osteocalcin that
was undercarboxylated (%GluOC). The vitamin K2 member,
MK-7, was shown to be more effective than phylloquinone
in carboxylating osteocalcin when the same molar dose of
0·22mmol/d (100mg phylloquinone; 142mg MK7) was
given to healthy adults for 40 d(102). Without a mechanistic
explanation, however, we do not yet know what degree of
osteocalcin carboxylation is optimal, particularly as the use
of different methodologies for calculating %GluOC gives
very different absolute values.
Nutritional interactions. There is some evidence that
vitamin K may act in concert with vitamin D, Ca, and possibly
other micronutrients to reduce bone loss. An enhanced effect
of combined vitamins K and D was postulated in both the
Dutch(119) and Scottish(120) supplementation studies with
1 mg and 200mg phylloquinone/d, respectively, and has
been suggested by the Japanese treatment of osteoporosis
with a regimen of MK-4 combined with 1a-hydroxycholecal-
ciferol. It is theoretically feasible that any synergy between
vitamins D and K derives from separate effects exerted
independently or alternatively from their concerted action on
common proteins or pathways; for instance by enhancing the
transcription (vitamin D) and post-translational modification
(vitamin K) of osteocalcin. Previous epidemiological evidence
that vitamin D might directly influence the g-carboxylation of
osteocalcin was not supported by the Scottish study(120).
Maximum levels for supplementation
Although not reflected by current European legislation,
vitamin K has a very wide safety margin. This is best illus-
trated by the widespread use of 45 mg/d doses of MK-4 for
the treatment of osteoporosis in Japan. For phylloquinone,
regular doses of up to 10 mg/d are used to treat patients
with potential malabsorption (for example, cystic fibrosis) or
to reverse warfarin over-anticoagulation. In cases of poisoning
with superwarfarin rodenticides, injections of 20–50 mg phyl-
loquinone/d may be required over several weeks to stabilise
coagulation. In many countries, including the USA, all new-
born infants are administered phylloquinone for the prevention
of vitamin K-deficiency bleeding.
A potential problem for introducing widespread vitamin K
supplementation is the large number of individuals taking
oral anticoagulants. The extent of the problem depends on
the level of supplementation, but a detailed dose–response
study suggested that food supplements providing 100mg
phylloquinone/d do not significantly interfere with oral
anticoagulant therapy(127). A recent paper actually suggests
that supplementation with regular daily vitamin K can have
beneficial effects on the stability of anticoagulant therapy(128).
Strontium
Bone health and benefits
The possibility of a beneficial effect of stable Sr on bone and
in the prevention of osteoporosis was first proposed in 1910 by
Lehnerdt(129), who administered strontium phosphate to dogs.
However, it was not until the 1950s that human evidence for
the benefits of Sr on bone began to appear. First, moderate
doses of strontium lactate were shown to improve the
deposition of Ca in human bone(130), and later a study in
thirty-two patients receiving an oral dose of 1·7 g strontium
lactate/d reported increased bone mass on X-ray in 78 % of
cases(131). Several animal and cell-culture studies documented
that Sr, particular strontium ranelate, can exert a positive
effect on bone formation, while inhibiting bone resorp-
tion(132 – 136). Strontium ranelate was demonstrated to have
both anti-resorptive and bone-forming activity, and was pre-
dicted to be of benefit in the treatment of bone diseases(137).
The therapeutic benefits of oral administration of 2 g strontium
ranelate/d in postmenopausal osteoporosis were confirmed in
2004 when a large placebo-controlled clinical trial in 1649
women reported early (after 1 year) and sustained (over
3 years) significant reduction in the risk of vertebral frac-
ture(138). Strontium ranelate’s anti-fracture efficacy was
shown to extend to non-vertebral fracture in 2005, following
publication of the results of a placebo-controlled study includ-
ing 5091 women with postmenopausal osteoporosis(139).
Treatment with 2 g strontium ranelate/d significantly reduced
the risk of non-vertebral and hip fracture over 3 years(139).
The vertebral, non-vertebral, and hip anti-fracture efficacy
has recently been confirmed over 5 years(140). The efficacy
of Sr in the primary and secondary prevention of osteoporosis
fracture was obtained with quantities of up to 680 mg/d corre-
sponding to 2 g strontium ranelate/d, and a daily intake of
0·13 mmol Sr/kg per d. All the reliable human data on Sr
were conducted with strontium ranelate under medical
supervision in a specific population with postmenopausal
osteoporosis(138 – 141). This agent is now recognised as a drug
treatment for osteoporosis in Europe.
The question of bioequivalence of the various Sr salts
remains unclear. Bioavailability in animal experiments
appears to vary from 5 to 25 % of the ingested dose under
normal physiological conditions(142), but comparative human
absorption data are incomplete and the relative beneficial
effects on bone unknown. The potential bone benefits for
the general population of oral supplementation with Sr have
not been assessed. It is unclear whether the benefits of
strontium ranelate extend to other salts. Further evaluations
including broader populations and other salts of Sr are
necessary.
Intake from diet. The average intake of Sr in a normal diet
is generally accepted to be between 1 and 2 mg/d in Western
populations(143). Consumption of vegetables grown in Sr-rich
soils may increase intake(144). Sr concentrations in drinking
water may vary from one geographic region to another,
but are generally agreed to lead to an intake between 2
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and 4 mg/d, considering that humans should drink about 2
litres/d(145). Although Sr is found in practically all foods, the
concentrations remain very low. The highest concentrations
are found in fish, seafood, nuts and leafy vegetables(143,146).
Other vegetables, cereals and fruit also contain significant
amounts of Sr, while meat and eggs have very low concen-
trations(147).
Necessity to supplement a normal diet. Sr does not have
any recognised biological role essential to health(148). No
requirement for dietary supplementation with Sr has been
established to date. None of the national and international
organisations mentions Sr as an essential nutrient or as part
of a nutritional strategy to improve bone health(2). No RDI
has been established because the decision to supplement a
normal diet must be made on the basis of observed
deficiencies in humans and no such cases have been identified
for Sr. The logical conclusion is that there is no need for
supplementation in the general population, even for prevention
of fracture in postmenopausal osteoporotic women for whom
the strontium ranelate salt is currently used as a treatment.
Risks, nutritional interactions, and consequences on bone
health
Although Sr is not toxic to humans, a number of animal
studies have demonstrated the detrimental consequences of
high doses of Sr (.4 mmol Sr/kg per d)(149). Such doses of
Sr were shown to induce skeletal abnormalities(129,150). Most
of these interactions concern Ca competition at the bone(151)
or intestinal level(152); these interactions could induce
hypocalcaemia(152). At elevated levels, Sr replaces Ca in
bone and can lead to the inhibition of calcification of epiphy-
seal cartilage and long-bone deformities in growing
rats(151,153). Oral administration of excess Sr in rats inhibited
the increase in Ca intestinal absorption normally stimulated
by vitamin D(154). The carbonate, gluconate and chloride
salts of Sr have also been reported to inhibit vitamin D activity
in rats(136), leading to bone malformation, while Sr ions have
been reported to produce rickets in rats by inhibiting the renal
production of vitamin D(155).
In humans, the induction of ‘Sr rickets’ has been observed
in children ingesting a low-vitamin D diet for 11 months
living in two different regions of Turkey with different soil
concentrations of Sr(144). The proportion of children with
rickets was significantly higher in the region with Sr-rich
soil than in the region with Sr-poor soil(144). This indicates
the possible importance of the effect of environmental Sr on
bone health, and illustrates how some populations could be
at high risk if Sr supplementation were implemented.
Interactions of Sr ions with lactose may increase the absorp-
tion of Sr(156). It has been suggested that this may present a
risk in overdose(150) since lactose decreases the discrimination
of Sr and Ca during intestinal absorption, particularly in chil-
dren(150,153,157). The vulnerability of children is reinforced by
the fact that the body burden of young children is greater than
in adults and so the bone consequences of Sr overdose would
be more severe(148). Raised levels of Sr have been shown to
have adverse effects in the bone of offspring of pregnant or
lactating animals(158,159), suggesting that Sr should not be
supplemented in pregnant or lactating women. In the presence
of impaired kidney function Sr supplementation should also be
avoided, since it could lead to osteomalacia as documented in
a rat model of chronic renal failure(160).
Although the detrimental effects of Sr only appear at elev-
ated levels, some populations may be at risk if they ingested
supplementary Sr without proper medical supervision.
Nevertheless, perusal of the literature reveals how little is
really known about Sr and its toxicity, and the studies on
the element are not always reliable(148). Apart from the studies
into the therapeutic applications of strontium ranelate(138,139),
there are no studies investigating the safety of long-term
oral exposure to other stable Sr salts in humans.
Magnesium
Mg is a nutritional bone component that has been poorly
studied for its role in bone health. Because bone undergoes
continuous remodelling, an adequate supply of Mg, as well
as other nutrients important to bone, is needed to support
bone formation. As with Ca, there is a potential risk of dietary
deficiency for Mg. Studies have shown that Mg deficiency
could affect bone growth and osteoblastic and osteoclastic
activity, induce osteopenia and bone fragility, and alter Ca
metabolism by affecting calciotropic hormones(161). Note
that there are no reliable biomarkers of Mg status or function.
RDI have been set on average intakes or balance estimates that
may not, therefore, reflect biological requirements.
Bone health and benefits
Nutritional properties. Approximately 60 % of the Mg in the
body is in bone. Mg influences mineral metabolism indirectly
through its role in ATP metabolism and as a cofactor for over
300 proteins, the calciotropic hormones and 1,25(OH)2D. Mg
also influences bone health by direct effects on bone quality,
decreasing hydroxyapatite crystal size, thereby preventing
the larger, more perfect mineral crystals that could lead to
brittle bone. Further, Mg also can indirectly influence bone
by acting as a buffer for the acid produced by the typical
Western diet, since Mg is found in green, leafy vegetables,
legumes and whole-grain products, nuts, seeds, fish and hard
water. Recent studies have found a positive association
between fruit and vegetable consumption and bone
health(162 – 165).
The scant clinical data available would support a bone
health benefit with dietary Mg. Small epidemiological
studies have found positive associations between Mg
intake and BMD. Preadolescent Mg intake is positively
related with bone mass in young women(166). High Mg
intakes have been associated with higher BMC in Australian
women(167), higher BMD at different sites in Scottish meno-
pausal women(163,168), Italian and American white postmeno-
pausal women(169,170), and elderly American white men and
women(162,171). In addition, higher Mg intakes have been
found to be linked with lower bone resorption markers in
Scottish women(163,168).
Clinical studies with Mg supplementation have also found a
positive impact on bone. Supplementation with 300 mg Mg/d
for 1 year (total Mg intake including diet, 484 mg/d)
significantly increased hip BMC in white adolescent
girls(172). Supplementation with 600 mg Mg/d (plus 500 mg
Ca/d) for 0·5 to 1 year resulted in mean increases of 11 % in
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BMD in postmenopausal women, which persisted at 2 years’
follow-up(173). Mg supplementation with 250 to 750 mg/d
(total Mg intake, 450–1050 mg/d) for 1·5 years resulted in
gains in BMD in most postmenopausal women, with no
reported side effects(174). In addition, Mg supplementation of
365 mg/d for 30 d (total Mg intake, 665 mg/d) reduced bone
turnover in young men(175).
Intake from diet. American RDI for Mg were increased in
1997 to 310 and 400 mg/d in younger (aged 19–30 years)
female and male adults, respectively, and to 320 and 420 mg/d
in female and male adults aged over 30 years(26). The European
Union population reference intake for adults is 150 to 500 mg
Mg/d, and the European Commission RDI is 300 mg/d(176).
The primary source of Mg is food, but consumption from
supplements is increasing due to the addition of Mg to
many commercially available products. Population studies in
the USA report low Mg intakes of 326 and 237 mg/d in
white men and women, respectively(177). In Europe, most
countries report an intake .300 mg/d in men, except in
Italy, which is below this level(178). In women, Mg intake is
about 300 mg/d, except in Italy, France and Spain; in the
elderly, intake is below this level in most countries. In
contrast, Mg intake is high in Germany, Denmark and
Hungary (about 416 mg/d).
Uncertainty regarding the necessity to supplement a normal
diet for bone health. According to the US RDI, Mg intake
would be suboptimal in most individuals, specifically
women from the southern European countries and the elderly.
This is due to an increased consumption of overly refined and/
or processed cereal-crop and carbohydrate food staples, which
removes most of the Mg.
On the basis of these observations, one may infer that diets
should be supplemented with Mg. However, a recent French
study reported that recommending Mg supplements would
only increase Mg intake by 10 %(179). Therefore, supplement-
ing food with Mg would appear to be a better strategy to
increase Mg intake to RDI levels in countries with relatively
low spontaneous intake. Whether such a food fortification
with Mg would improve bone health is not established.
Risk, nutritional interactions, and consequences on bone
health
Mg excess from a normal diet is rare. Studies of vegetarians in
Sweden and the USA report high Mg intake (440–615 mg/d),
with no associated health risks(180,181). Mg in excess or deficit
in rats (levels much below or above 0·25 % dietary Mg)
resulted in bone of abnormal appearance and chemical compo-
sition(182). Mild diarrhoea is the most undesirable effect of
orally administered easily dissociable Mg salts. No laxative
effects have been observed for Mg in adult men and
women, even during pregnancy and lactation, or in children
aged over 4 years, at doses up to 250 mg/d, which is
considered as the no-observed-adverse-effect level. No other
adverse health effects have been reported with Mg supplemen-
tation, even at levels as high as 1000 mg/d.
As shown in human studies, there are significant inter-
actions between Mg and the intestinal absorption of Fe
and Zn, probably owing to the inhibition of gastric acid by
Mg(183 – 185). Interactions with drugs such as tetracyclin,
penicillin and digoxin have also been reported(186). It has
been suggested that high-Ca diets could intensify Mg
deficiency; but short- and long-term studies of Mg balance
do not support this notion(187 – 189).
Maximum levels for supplementation
Assuming that future research will firmly establish the need
for dietary Mg enhancement for bone health, various amounts
have already been proposed. Former reports recommended
Mg supplementation as high as 600 mg/d for the elderly,
regardless of Mg status(173,174). A safe model for Mg addition
to foods has been developed in Europe, which proposes a
maximum level of 240 mg/d to be added to foods(176). If
10 % of all fortifiable foods were fortified with Mg, 10 mg
added to 100 kcal (418·4 kJ) of food portion will provide
200 mg Mg/d in a 2000 kcal (8368 kJ) diet. This would
increase usual dietary Mg intake from 200–300 mg/d to
400–500 mg/d, in women and in the elderly, and to
.500 mg/d in men.
Conclusion
Although the value of supplementary Ca and vitamin D in
bone health is well established, there is a distinct lack of
consensus regarding the other vitamins and minerals impli-
cated in bone health. Ca and vitamin D supplementation is
recommended in postmenopausal women and the elderly,
and in cases of osteoporosis. However, Ca supplementation
is recommended to the extent that the diet is poor in milk
and dairy products. The benefits of such a programme of sup-
plementation is supported by the results of randomised con-
trolled trials. Vitamin D is available in the diet from some
foods, but most comes from cutaneous synthesis and serum
levels may vary according to individual exposure to sunlight.
Current guidelines on vitamin D supplementation may not
have taken into account recent evidence, and underestimate
desirable intakes and maximal levels. Although P is essential
to bone health, supplementation is not recommended since
Western diets are almost systematically overgenerous in
terms of P content due to the high natural content of most
common foodstuffs and its widespread use as an additive in
food technology. Vitamin K appears to enhance the actions
of Ca and vitamin D, and may be important to bone health.
However, there is no agreement on maximal tolerated levels,
especially in individuals taking oral anticoagulants; whether
the general population would benefit from vitamin K sup-
plementation for bone health remains unclear. As regards Sr,
in contrast to the other minerals and vitamins, there is no pub-
lished nutritional requirement, no upper level has been
defined, and there is no established lower serum concentration
at which pathological symptoms appear. One Sr salt, strontium
ranelate, is currently authorised for the treatment for
postmenopausal osteoporosis, but there is no evidence that
Sr supplementation would be beneficial to bone health in the
general population. Mg is essential for skeletal health. Never-
theless, it is not firmly established that there would be a risk in
the general population of dietary Mg deficiency leading to
increased bone fragility. Therefore, despite the fact that in
the Western diet Mg is generally lower than recommended
intakes, current evidence is not strong enough to promote
enhancement of this element via fortification of foodstuffs.
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